The NGS-based test improves on a previous PCR-based version and detects circulating DNA from Epstein Barr virus that is shed from cancer cells.
Cincinnati Children's Hospital Medical Center researchers found that disease risk loci overlap with transcription factor binding sites.
Researchers use the CRISPR/Cas9 gene editing approach to limit herpesviruses replication.
In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.
In addition, Argene will provide BioMérieux with a portfolio of molecular tests for diagnosing infectious diseases in transplant and other immunocompromised patients.
BioMérieux plans to migrate Argene's test products onto a molecular diagnostic platform it is co-developing with Biocartis.
Quest's Focus Diagnostics gets CE Mark for Simplexa EBV and BK virus tests; Cepheid gets FDA nod for Xpert Flu test.
US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.
Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.
In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.
In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.